))
Protecting the product of innovation: IP and commercialization in cell and gene therapies
Manage episode 355403969 series 3291201
Το περιεχόμενο παρέχεται από το CCRM. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον CCRM ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.
Featuring:
Mark Taylor, Director of Commercialization, University Health Network
Dr. Irja Elliott Donaghue Technical & IP Specialist and Patent Agent, Notch Therapeutics
In the past, there was little evidence to challenge the idea that if a therapeutics developer did not hold a patent, it did not have anything to commercialize. In this episode, guests outline how the regenerative medicine industry changed that, proving the belief to be outdated, with some innovation being better protected by developers taking a “trade secrets” approach. Listen to hear guests examine intellectual property and commercialization issues in cell and gene therapies, with discussion of the complexities around the long-running patent battle over CRISPR technology, which has garnered international headlines in the last couple of years. Also discussed is how to protect and publish research, and the importance of having discussions with commercialization teams early in the technology development process.
Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.
18 επεισόδια
Μοίρασέ το
